Inovio Pharmaceuticals (LTS:0A43) Cyclically Adjusted Book per Share: $16.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A43 Inovio Pharmaceuticals Inc LTS:0A43
37 GF Score
Price $0.67
GF Value $0.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals Cyclically Adjusted Book per Share?

Inovio Pharmaceuticals LTS:0A43 +3.08% 37 Cyclically Adjusted Book per Share is $16.01 as of Mar. 2026. GuruFocus rates LTS:0A43 with a GF Score™ of 37/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $0.087. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.01 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Inovio Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -17.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -9.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -2.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Inovio Pharmaceuticals was 4.80% per year. The lowest was -14.30% per year. And the median was -5.50% per year.

As of today (2026-08-01), Inovio Pharmaceuticals's current stock price is $0.67005. Inovio Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $16.01. Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.85.


Inovio Pharmaceuticals  (LTS:0A43) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.67005/16.01
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inovio Pharmaceuticals was 18.50. The lowest was 0.04. And the median was 1.85.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Inovio Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.40 21.01 50.98 19.76 17.05

Inovio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.83 19.42 17.50 17.05 16.01

LTS:0A43 vs TELO, ELTX, ALPS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0A43
37GF Score
Inovio Pharmaceuticals Inc LTS:0A43
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.087/330.2130*330.2130
=0.087

Current CPI (Mar. 2026) = 330.2130.

Inovio Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 26.452 241.018 36.241
201609 23.829 241.428 32.592
201612 19.974 241.432 27.319
201703 17.020 243.801 23.053
201706 19.081 244.955 25.722
201709 21.531 246.819 28.806
201712 18.910 246.524 25.329
201803 14.949 249.554 19.781
201806 14.613 251.989 19.149
201809 13.161 252.439 17.216
201812 10.730 251.233 14.103
201903 9.547 254.202 12.402
201906 6.527 256.143 8.414
201909 4.082 256.759 5.250
201912 0.407 256.974 0.523
202003 15.158 258.115 19.392
202006 14.079 257.797 18.034
202009 23.201 260.280 29.435
202012 29.615 260.474 37.544
202103 33.339 264.877 41.563
202106 29.040 271.696 35.295
202109 25.874 274.310 31.147
202112 22.063 278.802 26.131
202203 18.811 287.504 21.605
202206 14.433 296.311 16.084
202209 12.828 296.808 14.272
202212 10.543 296.797 11.730
202303 9.099 301.836 9.954
202306 7.582 305.109 8.206
202309 6.146 307.789 6.594
202312 5.148 306.746 5.542
202403 4.041 312.332 4.272
202406 3.726 314.175 3.916
202409 2.823 315.301 2.957
202412 1.898 315.605 1.986
202503 1.397 319.799 1.442
202506 0.777 322.561 0.795
202509 -0.144 324.800 -0.146
202512 0.349 324.054 0.356
202603 0.087 330.213 0.087

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $16.01 mean?
Inovio Pharmaceuticals (LTS:0A43) has a Cyclically Adjusted Book per Share of $16.01 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Inovio Pharmaceuticals' current Cyclically Adjusted Book per Share is $16.01. Overall, Inovio Pharmaceuticals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Cyclically Adjusted Book per Share compare to TELO and ELTX?
Inovio Pharmaceuticals' Cyclically Adjusted Book per Share of $16.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Cyclically Adjusted Book per Share is $16.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (LTS:0A43) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.67 — trading 219.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $16.01. Inovio Pharmaceuticals' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Inovio Pharmaceuticals (LTS:0A43), the current Cyclically Adjusted Book per Share is $16.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (LTS:0A43) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.67 is trading 219.1% above its estimated GF Value™ of $0.21. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for LTS:0A43:

  • Cyclically Adjusted Book per Share: $16.01
  • GF Value™: $0.21 vs. price of $0.67 (219.1% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the LTS:0A43 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inovio Pharmaceuticals Business Description

Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
37GF Score

Get the complete analysis for LTS:0A43

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price
$0.21
GF Value